Tag: neoantigen targeted therapies market size

Uncover key drivers, emerging technologies, and competitive movements shaping the neoantigen targeted therapies market from 2026–2035 with trusted insights from The Business Research Company

How much larger will the Neoantigen Targeted Therapies Market be in 2030 compared with 2026?

The market size for neoantigen targeted therapies has witnessed rapid expansion over recent years. It is anticipated to increase from $4.71 billion in 2025 to $6.39 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 35.8%. The historical growth in this sector is attributable to various factors including limited immunotherapy options, the slow progress in cancer vaccine development, the initial stages of genomic sequencing usage, restricted access to clinical trials, and a continued dependence on traditional oncology treatments.

The neoantigen targeted therapies market is projected to experience significant expansion in the coming years. This market is forecast to reach $21.52 billion by 2030, demonstrating a robust compound annual growth rate (CAGR) of 35.5%. The projected growth is primarily driven by the rapid advancement of personalized cancer therapies, increased investment in genomic sequencing, the expansion of clinical research collaborations, a rising adoption of combination immunotherapies, and a growing demand for precision oncology solutions. Noteworthy trends during this forecast period include the increasing uptake of personalized cancer vaccines, an expansion of targeted immunotherapy research pipelines, a rise in clinical trials for neoantigen-based combination therapies, the growing demand for early genetic profiling in oncology, and a surge in the development of TIL-based therapeutic approaches.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11944&type=smp

What Drivers Are Guiding Growth Patterns In The Neoantigen Targeted Therapies Market?

The increasing prevalence of precision oncology is projected to stimulate the expansion of the neoantigen targeted therapies market moving forward. Precision oncology is a cancer treatment approach that employs detailed genetic and molecular data from a patient’s tumor to direct the selection of targeted therapies. This method integrates neoantigen-targeted therapies by utilizing advanced genomic analysis to identify distinct neoantigens expressed by an individual’s cancer cells. The application of neoantigen-targeted therapies within precision oncology represents a strategy to address the specific genetic makeup of each patient’s tumor, offering a more tailored and effective treatment option. For example, in March 2024, information from the Precision Oncology Clinical Trials & Statistics 2024 report, published by Novotech, an Australia-based full-service clinical contract research organization involved in developing innovative therapeutics, revealed that by November 2023, twelve treatments had obtained FDA approval for specific biomarker-selected indications, with six of these also incorporated into the NCCN guidelines. By the close of the year, 43% of the 217 FDA-approved oncology therapies were designated as precision oncology, and 78 of these therapies incorporated DNA or NGS-detectable biomarkers, emphasizing the growing significance of biomarker-guided treatments in cancer care. Thus, the growth in precision oncology is propelling the expansion of the neoantigen targeted therapies market.

How Is The Neoantigen Targeted Therapies Market Divided Into Segments?

The neoantigen targeted therapies market covered in this report is segmented –

1) By Type: Monotherapy, Combination Therapy

2) By Immunotherapy Type: DNA Or RNA-Based Vaccines, Protein-Based Vaccines, Dendritic Cell Vaccines, TIL-Based Therapies

3) By Target Disease Indication: Colorectal Cancer, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Bone Cancer, Gynecological Cancer

4) By Route Of Administration: Intradermal, Intravenous, Subcutaneous

5) By Application: Medical Research Institution, Hospitals and Clinics, Other Applications

Subsegments:

1) By Monotherapy: Individual Neoantigen-Targeted Treatments

2) By Combination Therapy: Neoantigen-Targeted Therapies Combined With Other Immunotherapies, Neoantigen-Targeted Therapies Combined With Chemotherapy, Neoantigen-Targeted Therapies Combined With Targeted Therapies

Which Trends Are Influencing The Performance And Direction Of The Neoantigen Targeted Therapies Market?

Leading firms within the neoantigen targeted therapies market are employing a strategic partnership strategy to customize neoantigen vaccines and monoclonal antibody medications, aiming to address the difficulties posed by current immunotherapy for solid tumor treatment. These alliances involve businesses utilizing each other’s strengths and assets to attain shared advantages and successful outcomes. As an illustration, in April 2023, Moderna, Inc., a pharmaceutical and biotechnology firm from the US, joined forces with Merck & Co., Inc., another US pharmaceutical company, to introduce mRNA-4157 (V940). This experimental individualized neoantigen therapy (INT) is engineered to elicit a specific anti-tumor immune response corresponding to the distinct mutational profile of a patient’s tumor. mRNA-4157 (V940) functions by encoding as many as 34 neoantigens to stimulate T cell reactions, thereby boosting the body’s capacity to identify and eliminate tumor cells when administered alongside Merck’s immunotherapy KEYTRUDA. The objective of this combined treatment is to enhance recurrence-free survival for individuals with high-risk resected melanoma.

Which Major Industry Participants Are Leading The Neoantigen Targeted Therapies Market Growth?

Major companies operating in the neoantigen targeted therapies market are F. Hoffmann-La Roche AG, Merck and Co. Inc., Bristol Myers Squibb Company, Kite Pharma Inc., Amgen Inc., Moderna Inc., BioNTech SE, Bavarian Nordic Inc., Advaxis Inc., Immatics NV, Iovance Biotherapeutics Inc., Agenus Inc., Achilles Therapeutics Plc, Medigene AG, Gritstone Bio Inc., SQZ Biotechnologies Company, Aduro BioTech Inc., Inovio Pharmaceuticals Inc., Gradalis Inc., EpiVax Inc., ISA Pharmaceuticals BV, Vaxon Biotech SA, Ziopharm Oncology, Genocea Biosciences Inc., Cellular Biomedicine Group Inc., Immunovaccine Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/neoantigen-targeted-therapies-global-market-report

Which Geographic Areas Are Emerging As Strong Markets For The Neoantigen Targeted Therapies Market?

North America was the largest region in the neoantigen targeted therapies market in 2025. The regions covered in the neoantigen targeted therapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Neoantigen Targeted Therapies Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=11944&type=smp

Browse Through More Reports Similar to the Global Neoantigen Targeted Therapies Market 2026, By The Business Research Company

Leukemia Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/leukemia-therapeutics-global-market-report

Targeted Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/targeted-therapy-global-market-report

Anti Neoplastic Agents Market Report 2026

https://www.thebusinessresearchcompany.com/report/anti-neoplastic-agents-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Is The Present And Forecasted Size Of The Neoantigen Targeted Therapies Market?

The market size for neoantigen targeted therapies has seen a significant growth in the past few years. It is projected to increase from $3.4 billion in 2024 to $4.71 billion in 2025, growing at a compound annual growth rate (CAGR) of 38.3%. The historical growth of the market owes to progress in genomic sequencing, the development of immunotherapy, understanding of tumor immunology, the clinical success of checkpoint inhibitors, and improvements in molecular profiling.

The size of the market for neoantigen targeted therapies is anticipated to expand significantly in the forthcoming years. The market is projected to swell to a value of $15.93 billion in 2029, with a compound annual growth rate (CAGR) of 35.7%. The predicted growth during this period can be ascribed to progress in bioinformatics, the broadening of precision medicine, advancement in neoantigen vaccines, strategic therapeutic combinations, and biomarker validation. During the forecast period, prevalent trends include management of neoantigen resistance, therapies involving neoantigen-primed adoptive cells, combinatorial therapies based on neoantigen, assimilation of real-world data, and enhanced predictive models.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11944&type=smp

What Underlying Factors Are Supporting The Neoantigen Targeted Therapies Market Growth?

The neoantigen targeted therapies market is anticipated to flourish due to the rising number of cancer cases. The term “incidence of cancer” refers to the emergence of fresh cancer cases within a certain population bracket over a specified duration. These neoantigen-targeted therapies are typically employed conjointly to address various forms of cancer. The American Cancer Society (ACS), a voluntary health organization based in the U.S, noted that in 2022, there was a stark increase in new cancer cases with 1.9 million individuals affected, a clear upsurge from the preceding years. Moreover, the year 2022 also witnessed about 609,360 cancer-related deaths in the U.S, underlining the serious impact and harshness of this ailment on individuals and their loved ones. Consequently, the proliferating instances of cancer cases are fueling the expansion of the neoantigen targeted therapies market.

How Does The Neoantigen Targeted Therapies Market Differ By Segment?

The neoantigen targeted therapiesmarket covered in this report is segmented –

1) By Type: Monotherapy, Combination Therapy

2) By Immunotherapy Type: DNA Or RNA-Based Vaccines, Protein-Based Vaccines, Dendritic Cell Vaccines, TIL-Based Therapies

3) By Target Disease Indication: Colorectal Cancer, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Bone Cancer, Gynecological Cancer

4) By Route Of Administration: Intradermal, Intravenous, Subcutaneous

5) By Application: Medical Research Institution, Hospital, And Clinic, Other Applications

Subsegments:

1) By Monotherapy: Individual Neoantigen-Targeted Treatments

2) By Combination Therapy: Neoantigen-Targeted Therapies Combined With Other Immunotherapies; Neoantigen-Targeted Therapies Combined With Chemotherapy; Neoantigen-Targeted Therapies Combined With Targeted Therapies

How Are Global Trends Impacting The Development Of The Neoantigen Targeted Therapies Market?

Key players in the neoantigen targeted therapies market are engaging in strategic alliances to personalize cancer treatments and address issues that hinder current immunotherapy options for solid tumors. These strategic alliances allow firms to utilize each other’s capabilities and resources to mutually benefit and succeed. An example of this occurred in January 2023 when BioNTech SE, a biotech company based in Germany, joined forces with the UK Government. The purpose of this alliance is to progress the development of personalized mRNA cancer immunotherapies. It aims to provide specialized treatments for as many as 10,000 patients by 2030 and encompasses several pivotal areas, including cancer immunotherapy development, infectious disease vaccine research, and the establishment of a research and development hub in Cambridge. This initiative is expected to tap into the UK’s clinical trial structure and health data sets to enhance patient enrollment and choose appropriate sites for BioNTech’s mRNA treatments. The first clinical trials from the company in the UK are planned for later this year. These trials will focus on cancer vaccines that may potentially be incorporated into standard treatment regimens if they demonstrate efficacy.

Who Are The Global Leaders Steering The Neoantigen Targeted Therapies Market Forward?

Major companies operating in the neoantigen targeted therapies market include F. Hoffmann-La Roche AG, Merck and Co. Inc., Bristol Myers Squibb Company, Eli Lilly and Company, Kite Pharma Inc., Gilead Sciences Inc., Amgen Inc., Moderna Inc., BioNTech SE, Bavarian Nordic Inc., Advaxis Inc., Immatics NV, Precision Biologics Inc., Iovance Biotherapeutics Inc., Agenus Inc., Achilles Therapeutics Plc, Medigene AG, Gritstone Bio Inc., SQZ Biotechnologies Company, Aduro BioTech Inc., Inovio Pharmaceuticals Inc., Gradalis Inc., EpiVax Inc., ISA Pharmaceuticals BV, Vaxon Biotech SA, Ziopharm Oncology, Genocea Biosciences Inc., Cellular Biomedicine Group Inc., Immunovaccine Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/neoantigen-targeted-therapies-global-market-report

Which Region Is Likely To Register The Fastest Growth In The Neoantigen Targeted Therapies Market?

North America was the largest region in the neoantigen targeted therapies market in 2024. The regions covered in the neoantigen targeted therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=11944&type=smp

Browse Through More Reports Similar to the Global Neoantigen Targeted Therapies Market 2025, By The Business Research Company

Blood Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report

Cancer Biologics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

Rituximab Biosimilar Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/rituximab-biosimilar-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Market Value Is The Neoantigen Targeted Therapies Industry Expected To Reach By 2029, Starting From 2025 Levels?

The neoantigen targeted therapies market size has seen a substantial increase in recent years. This market is projected to expand from $3.4 billion in 2024 to $4.71 billion in 2025, reflecting a compound annual growth rate (CAGR) of 38.3%. The historical growth of this market can be attributed to advancements in genomic sequencing, immunotherapy evolution, improved understanding of tumor immunology, the clinical success of checkpoint inhibitors, and progress in molecular profiling advancements.

The neoantigen targeted therapies market size is anticipated to witness significant expansion in the coming years. It is projected to reach ” $15.93 billion in 2029, demonstrating a compound annual growth rate (CAGR) of 35.7%. This growth over the forecast period stems from advancements in bioinformatics, the expansion of precision medicine, ongoing neoantigen vaccine development, strategic therapeutic combination approaches, and biomarker validation. Notable trends anticipated during the forecast period encompass neoantigen resistance management, the emergence of neoantigen-primed adoptive cell therapies, combinatorial neoantigen-based therapies, the integration of real-world data, and enhanced predictive models.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11944&type=smp

What Are The Top Growth Drivers Impacting The Neoantigen Targeted Therapies Market Outlook?

The escalating occurrence of cancer cases is anticipated to drive the expansion of the neoantigen targeted therapies market. The incidence of cancer denotes the number of new cases identified within a particular population over a given period. Neoantigen-targeted therapies are frequently utilized in combination to address various cancer types. For instance, the American Cancer Society (ACS) reported 1.9 million new cancer cases in the United States in 2022, marking a notable increase from prior years. Additionally, in 2022, approximately 609,360 deaths in the US were attributed to cancer, highlighting the significant impact and severity of this disease on individuals and their families. Consequently, the rising incidence of cancer cases is fueling the growth of the neoantigen targeted therapies market.

What Are The Leading Segments Analyzed In The Neoantigen Targeted Therapies Market?

The neoantigen targeted therapiesmarket covered in this report is segmented –

1) By Type: Monotherapy, Combination Therapy

2) By Immunotherapy Type: DNA Or RNA-Based Vaccines, Protein-Based Vaccines, Dendritic Cell Vaccines, TIL-Based Therapies

3) By Target Disease Indication: Colorectal Cancer, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Bone Cancer, Gynecological Cancer

4) By Route Of Administration: Intradermal, Intravenous, Subcutaneous

5) By Application: Medical Research Institution, Hospital, And Clinic, Other Applications

Subsegments:

1) By Monotherapy: Individual Neoantigen-Targeted Treatments

2) By Combination Therapy: Neoantigen-Targeted Therapies Combined With Other Immunotherapies; Neoantigen-Targeted Therapies Combined With Chemotherapy; Neoantigen-Targeted Therapies Combined With Targeted Therapies

Which Trends Are Impacting The Neoantigen Targeted Therapies Market?

Major companies within the neoantigen targeted therapies market are adopting a strategic partnership approach to personalize cancer therapies, aiming to overcome challenges associated with current immunotherapy in treating solid tumors. Strategic partnerships are defined as a process where companies utilize each other’s strengths and resources to achieve mutual benefits and success. For instance, in January 2023, BioNTech SE, a Germany-based biotechnology company, formed a partnership with the Government of the United Kingdom, a UK-based organization, to advance personalized mRNA cancer immunotherapies. This collaboration intends to deliver tailored treatments to as many as 10,000 patients by 2030 and encompasses several critical areas, including the development of cancer immunotherapies, research on infectious disease vaccines, and the establishment of a research and development hub in Cambridge. The initiative will leverage the UK’s clinical trial infrastructure and health data resources to enhance patient recruitment and select appropriate trial sites for BioNTech’s mRNA treatments. The company plans to initiate its initial clinical trials in the UK later this year, focusing on cancer vaccines that could potentially integrate into standard treatment protocols if their effectiveness is confirmed.

Which Leading Companies Dominate The Neoantigen Targeted Therapies Market Share?

Major companies operating in the neoantigen targeted therapies market include F. Hoffmann-La Roche AG, Merck and Co. Inc., Bristol Myers Squibb Company, Eli Lilly and Company, Kite Pharma Inc., Gilead Sciences Inc., Amgen Inc., Moderna Inc., BioNTech SE, Bavarian Nordic Inc., Advaxis Inc., Immatics NV, Precision Biologics Inc., Iovance Biotherapeutics Inc., Agenus Inc., Achilles Therapeutics Plc, Medigene AG, Gritstone Bio Inc., SQZ Biotechnologies Company, Aduro BioTech Inc., Inovio Pharmaceuticals Inc., Gradalis Inc., EpiVax Inc., ISA Pharmaceuticals BV, Vaxon Biotech SA, Ziopharm Oncology, Genocea Biosciences Inc., Cellular Biomedicine Group Inc., Immunovaccine Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/neoantigen-targeted-therapies-global-market-report

What Are The Regional Market Dynamics Impacting The Neoantigen Targeted Therapies Industry?

North America was the largest region in the neoantigen targeted therapies market in 2024. The regions covered in the neoantigen targeted therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Neoantigen Targeted Therapies Market Report:

https://www.thebusinessresearchcompany.com/customise?id=11944&type=smp

Browse Through More Reports Similar to the Global Neoantigen Targeted Therapies Market 2025, By The Business Research Company

Blood Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report

Cancer Biologics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

Rituximab Biosimilar Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/rituximab-biosimilar-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#What Is the Current and Projected Market Size of the Neoantigen Targeted Therapies Market Through 2034?#_x000D_

The market size for neoantigen targeted therapies has experienced a rapid increase in recent years. The market value is projected to expand from $3.4 billion in 2024 to $4.71 billion in 2025, reflecting a compound annual growth rate (CAGR) of 38.3%. This impressive growth during the historical period can be credited to developments in genomic sequencing, progression in immunotherapy, increased comprehension of tumor immunology, clinical victories of checkpoint inhibitors, and enhancements in molecular profiling._x000D_

_x000D_

Expectations are high for the neoantigen targeted therapies market to undergo significant expansion in the coming years. The market is projected to reach a size of $15.93 billion by 2029 with a compound annual growth rate (CAGR) of 35.7%. This projected increase within the forecast period can be linked to advancements in areas such as bioinformatics, the growth of precision medicine, the development of neoantigen vaccines, therapeutic combination strategies, and biomarker validation. Significant developments within the projection period include managing neoantigen resistance, adopting neoantigen-primed cell therapies, executing neoantigen-based combinatorial therapies, incorporating real-world data, and enhancing predictive models._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=11944&type=smp_x000D_

_x000D_

#Which Factors and External Forces Are Driving Demand in the Neoantigen Targeted Therapies Market?#_x000D_

The rise in the number of cancer cases is anticipated to spur the expansion of the neoantigen targeted therapies market. The term ‘incidence of cancer’ refers to the emergence of new cancer cases in a given populace during a specific timeframe. To treat various kinds of cancer, neoantigen-focused treatments are typically used in collaboration. For instance, the American Cancer Society (ACS), a voluntary health organisation based in the US, reported 1.9 million fresh cases of cancer in the United States in 2022, indicating a considerable rise in comparison to previous years. Moreover, in 2022, around 609,360 deaths in the US were attributed to cancer, underscoring the intense severity and adverse influence of this illness on individuals and their families. Consequently, the surge in cancer incidence is facilitating the neoantigen targeted therapies market’s growth._x000D_

_x000D_

#Which Segments in the Neoantigen Targeted Therapies Offer the Most Growth?#_x000D_

The neoantigen targeted therapiesmarket covered in this report is segmented – _x000D_

_x000D_

1) By Type: Monotherapy, Combination Therapy_x000D_

2) By Immunotherapy Type: DNA Or RNA-Based Vaccines, Protein-Based Vaccines, Dendritic Cell Vaccines, TIL-Based Therapies_x000D_

3) By Target Disease Indication: Colorectal Cancer, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Bone Cancer, Gynecological Cancer_x000D_

4) By Route Of Administration: Intradermal, Intravenous, Subcutaneous_x000D_

5) By Application: Medical Research Institution, Hospital, And Clinic, Other Applications_x000D_

_x000D_

Subsegments:_x000D_

1) By Monotherapy: Individual Neoantigen-Targeted Treatments_x000D_

2) By Combination Therapy: Neoantigen-Targeted Therapies Combined With Other Immunotherapies; Neoantigen-Targeted Therapies Combined With Chemotherapy; Neoantigen-Targeted Therapies Combined With Targeted Therapies _x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=11944&type=smp_x000D_

_x000D_

#What Are the Fastest-Growing Geographies in the #Which Factors and External Forces Are Driving Demand in the Neoantigen Targeted Therapies Market?# Market?#_x000D_

North America was the largest region in the neoantigen targeted therapies market in 2024. The regions covered in the neoantigen targeted therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Which Cutting-Edge Market Trends Are Expected to Drive theNeoantigen Targeted Therapies Market’s Growth?#_x000D_

Key players in the neoantigen targeted therapies market are utilizing strategic partnerships to tailor cancer treatments, addressing the limitations of current immunotherapy methods for treating solid tumors. Essentially, strategic partnerships work by allowing companies to utilize each other’s unique capabilities and resources in order to achieve shared success. For instance, in January 2023, BioNTech SE, a biotechnology firm from Germany, decided to collaborate with the Government of the United Kingdom. This alliance is set to deliver personalized mRNA cancer immunotherapies to up to 10,000 patients by 2030, encompassing several crucial aspects such as cancer immunotherapy development, infectious disease vaccine research, and the establishment of a research and development center in Cambridge. By utilizing the UK’s clinical trial framework and health data reserves, this initiative seeks to enhance patient recruitment and pick suitable trial locations for BioNTech’s mRNA treatments. Moreover, the firm has plans to kick off its inaugural clinical trials in the UK later this year, with an emphasis on cancer vaccines that could potentially be assimilated into mainstream treatment methods if found to be effective._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/neoantigen-targeted-therapies-global-market-report_x000D_

_x000D_

#What Are the Key Elements That Define the Neoantigen Targeted Therapies Market?#_x000D_

Neoantigen-targeted therapies are a type of precision medicine that concentrates on neoantigens in cancer cells. Neoantigens are distinct antigens that are derived from genetic abnormalities or modifications present in cancer cells. It is used to harness the body’s immune system to recognize and attack cancer cells specifically by targeting these neoantigens._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11944_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Europe +44 7882 955267_x000D_

Asia & Others +44 7882 955267 & +91 8897263534_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Neoantigen Targeted Therapies Market Grown from 2024 to 2025?

In the last few years, the market for neoantigen targeted therapies has experienced a significant expansion. The market is projected to increase from $3.4 billion in 2024 to $4.72 billion in 2025, with a compound annual growth rate (CAGR) of 38.7%. Factors contributing to the growth during the historic period include advancements in genomic sequencing, evolution of immunotherapy, enhanced understanding of tumor immunology, the clinical success of checkpoint inhibitors, and progress in molecular profiling.

What Growth Rate Is Anticipated for the Neoantigen Targeted Therapies Market in the Coming Years?

The market for neoantigen targeted therapies is anticipated to witness an exponential expansion over the next few years. The market value is projected to reach $16.01 billion in 2029, growing at a compound annual growth rate (CAGR) of 35.7%. This anticipated growth during the forecast period can be linked to the advancement in bioinformatics, the growth of precision medicine, the development of neoantigen vaccines, the strategic combination of therapeutics, and biomarker validation. Key trends for the forecast period include the management of neoantigen resistance, neoantigen-primed adoptive cell therapies, combined neoantigen-based therapies, the incorporation of real-world data, and improved predictive models.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11944&type=smp

Who Are the Leading Companies in the Neoantigen Targeted Therapies Market?

Major companies operating in the neoantigen targeted therapies market include F. Hoffmann-La Roche AG, Merck and Co. Inc., Bristol Myers Squibb Company, Eli Lilly and Company, Kite Pharma Inc., Gilead Sciences Inc., Amgen Inc., Moderna Inc., BioNTech SE, Bavarian Nordic Inc., Advaxis Inc., Immatics NV, Precision Biologics Inc., Iovance Biotherapeutics Inc., Agenus Inc., Achilles Therapeutics Plc, Medigene AG, Gritstone Bio Inc., SQZ Biotechnologies Company, Aduro BioTech Inc., Inovio Pharmaceuticals Inc., Gradalis Inc., EpiVax Inc., ISA Pharmaceuticals BV, Vaxon Biotech SA, Ziopharm Oncology, Genocea Biosciences Inc., Cellular Biomedicine Group Inc., Immunovaccine Inc.

What Are the Key Drivers of the Neoantigen Targeted Therapies Market?

The neoantigen targeted therapies market’s growth is anticipated to be fueled by the increasing number of cancer occurrences. The term cancer incidence relates to the total number of new cancer diagnoses within a specific demographic over a set time frame. Neoantigen-targeted treatments are typically combined to combat various cancer types. For example, according to the American Cancer Society, a voluntary health organization based in the US, there were about 1.9 million new cancer diagnoses in the US in 2022, showing a substantial rise from prior years. In addition, approximately 609,360 deaths were linked to cancer in the US in 2022, highlighting the profound seriousness and the overwhelming effect this disease has on sufferers and their loved ones. Hence, the upsurge in cancer incidence is a critical driving factor for the expanded growth of the neoantigen targeted therapies market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=11944&type=smp

What Are the Key Market Segments in the Neoantigen Targeted Therapies Industry?

The neoantigen targeted therapies market covered in this report is segmented –

1) By Type: Monotherapy, Combination Therapy

2) By Immunotherapy Type: DNA Or RNA-Based Vaccines, Protein-Based Vaccines, Dendritic Cell Vaccines, TIL-Based Therapies

3) By Target Disease Indication: Colorectal Cancer, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Bone Cancer, Gynecological Cancer

4) By Route Of Administration: Intradermal, Intravenous, Subcutaneous

5) By Application: Medical Research Institution, Hospital, And Clinic, Other Applications

Subsegments:

1) By Monotherapy: Individual Neoantigen-Targeted Treatments

2) By Combination Therapy: Neoantigen-Targeted Therapies Combined With Other Immunotherapies, Neoantigen-Targeted Therapies Combined With Chemotherapy, Neoantigen-Targeted Therapies Combined With Targeted Therapies

What Are the Latest Trends in the Neoantigen Targeted Therapies Market?

In order to overcome the hurdles of current immunotherapy in treating solid tumors, leading organizations in the neoantigen targeted therapies sector are adopting a collaborative strategy to individualize cancer treatments. This approach enables companies to tap into each other’s unique strengths and resources for shared benefits and triumphs. Take for example the collaboration in January 2023 between BioNTech SE, a biotech firm based in Germany, and the UK Government. Their joint effort seeks to provide personalized mRNA cancer immunotherapies for around 10,000 patients by 2030. It encompasses several key domains like the advancement of cancer immunotherapies, infectious disease vaccine research, and the establishment of a research and development centre in Cambridge. Using the UK’s clinical trial infrastructure and health data resources, they aim to enhance patient recruitment and select the proper trial locations for BioNTech’s mRNA therapies. The company intends to kickstart its initial clinical trials in the UK within the year, with a focus on cancer vaccines that could potentially be incorporated into standard treatment procedures given their effectiveness.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/neoantigen-targeted-therapies-global-market-report

What Are the Key Regional Markets in the Neoantigen Targeted Therapies Industry?

North America was the largest region in the neoantigen targeted therapies market in 2024. The regions covered in the neoantigen targeted therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11944

This Report Delivers Insight On:

1. How big is the neoantigen targeted therapies market, and how is it changing globally?

2. Who are the major companies in the neoantigen targeted therapies market, and how are they performing?

3. What are the key opportunities and risks in the neoantigen targeted therapies market right now?

4. Which products or customer segments are growing the most in the neoantigen targeted therapies market?

5. What factors are helping or slowing down the growth of the neoantigen targeted therapies market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the neoantigen targeted therapies industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

How Has The Neoantigen Targeted Therapies Market Size Shifted, And What Is the Outlook Through 2034?

In the last few years, the market for neoantigen targeted therapies has experienced a significant expansion. The market is projected to increase from $3.4 billion in 2024 to $4.72 billion in 2025, with a compound annual growth rate (CAGR) of 38.7%. Factors contributing to the growth during the historic period include advancements in genomic sequencing, evolution of immunotherapy, enhanced understanding of tumor immunology, the clinical success of checkpoint inhibitors, and progress in molecular profiling.

The market for neoantigen targeted therapies is anticipated to witness an exponential expansion over the next few years. The market value is projected to reach $16.01 billion in 2029, growing at a compound annual growth rate (CAGR) of 35.7%. This anticipated growth during the forecast period can be linked to the advancement in bioinformatics, the growth of precision medicine, the development of neoantigen vaccines, the strategic combination of therapeutics, and biomarker validation. Key trends for the forecast period include the management of neoantigen resistance, neoantigen-primed adoptive cell therapies, combined neoantigen-based therapies, the incorporation of real-world data, and improved predictive models.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11944&type=smp

What are the Fundamental Drivers and Innovations Shaping the Neoantigen Targeted Therapies Market?

The neoantigen targeted therapies market’s growth is anticipated to be fueled by the increasing number of cancer occurrences. The term cancer incidence relates to the total number of new cancer diagnoses within a specific demographic over a set time frame. Neoantigen-targeted treatments are typically combined to combat various cancer types. For example, according to the American Cancer Society, a voluntary health organization based in the US, there were about 1.9 million new cancer diagnoses in the US in 2022, showing a substantial rise from prior years. In addition, approximately 609,360 deaths were linked to cancer in the US in 2022, highlighting the profound seriousness and the overwhelming effect this disease has on sufferers and their loved ones. Hence, the upsurge in cancer incidence is a critical driving factor for the expanded growth of the neoantigen targeted therapies market.

How Is the Neoantigen Targeted Therapies Market Segmented?

The neoantigen targeted therapies market covered in this report is segmented –

1) By Type: Monotherapy, Combination Therapy

2) By Immunotherapy Type: DNA Or RNA-Based Vaccines, Protein-Based Vaccines, Dendritic Cell Vaccines, TIL-Based Therapies

3) By Target Disease Indication: Colorectal Cancer, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Bone Cancer, Gynecological Cancer

4) By Route Of Administration: Intradermal, Intravenous, Subcutaneous

5) By Application: Medical Research Institution, Hospital, And Clinic, Other Applications

Subsegments:

1) By Monotherapy: Individual Neoantigen-Targeted Treatments

2) By Combination Therapy: Neoantigen-Targeted Therapies Combined With Other Immunotherapies, Neoantigen-Targeted Therapies Combined With Chemotherapy, Neoantigen-Targeted Therapies Combined With Targeted Therapies

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=11944&type=smp

Which Regions Are Driving the Next Phase of the Neoantigen Targeted Therapies Market Growth?

North America was the largest region in the neoantigen targeted therapies market in 2024. The regions covered in the neoantigen targeted therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Trends Are Shaping the Future of the Neoantigen Targeted Therapies Market?

In order to overcome the hurdles of current immunotherapy in treating solid tumors, leading organizations in the neoantigen targeted therapies sector are adopting a collaborative strategy to individualize cancer treatments. This approach enables companies to tap into each other’s unique strengths and resources for shared benefits and triumphs. Take for example the collaboration in January 2023 between BioNTech SE, a biotech firm based in Germany, and the UK Government. Their joint effort seeks to provide personalized mRNA cancer immunotherapies for around 10,000 patients by 2030. It encompasses several key domains like the advancement of cancer immunotherapies, infectious disease vaccine research, and the establishment of a research and development centre in Cambridge. Using the UK’s clinical trial infrastructure and health data resources, they aim to enhance patient recruitment and select the proper trial locations for BioNTech’s mRNA therapies. The company intends to kickstart its initial clinical trials in the UK within the year, with a focus on cancer vaccines that could potentially be incorporated into standard treatment procedures given their effectiveness.

View the full report here:

https://www.thebusinessresearchcompany.com/report/neoantigen-targeted-therapies-global-market-report

How Is the Neoantigen Targeted Therapies Market Defined and What Are Its Core Parameters?

Neoantigen-targeted therapies are a type of precision medicine that concentrates on neoantigens in cancer cells. Neoantigens are distinct antigens that are derived from genetic abnormalities or modifications present in cancer cells. It is used to harness the body’s immune system to recognize and attack cancer cells specifically by targeting these neoantigens.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11944

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

How Are Key Drivers Contributing to the Growth and Expansion of the Neoantigen Targeted Therapies Market?

The rise in cancer occurrences is anticipated to fuel the expansion of the neoantigen targeted therapies market in the future. The term cancer incidence is used to describe the rate of new cancer cases within a certain demographic over a specified timeframe. Neoantigen-targeted treatments are typically combined to address various types of cancer. For example, in 2022 the American Cancer Society (ACS), an American voluntary health institution, shared that the United States saw a drastic rise in new cancer cases with 1.9 million reported incidences, a considerable surge compared to past years. Moreover, approximately 609,360 cancer-related deaths were recorded in the US in 2022, highlighting the profound effect and seriousness of this illness on individuals and their loved ones. Hence, the escalating number of cancer cases is stimulating the expansion of the neoantigen targeted therapies market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11944&type=smp

#What Long-Term Growth Rate is Expected for theNeoantigen Targeted Therapies Market Between 2025 and 2034?

The market size for neoantigen targeted therapies has experienced rapid expansion in the past few years. Expected to escalate from $3.4 billion in 2024 to $4.72 billion in 2025, it indicates a compound annual growth rate (CAGR) of 38.7%. The surge during the historical stretch is largely due to progress in genomic sequencing, the refinement of immunotherapy, increased comprehension of tumor immunology, the clinical effectiveness of checkpoint inhibitors, and advances in molecular profiling.

In the coming years, the market for neoantigen targeted therapies is projected to experience significant expansion, reaching $16.01 billion by 2029 with a compound annual growth rate (CAGR) of 35.7%. The anticipated growth within the forecasted period can be linked to advancements in the fields of bioinformatics, expansion of precision medicine, development of neoantigen vaccines, and strategies for therapeutic combination and biomarker validation. Key market trends to watch during this period include the management of neoantigen resistance, the adoption of neoantigen-primed cell therapies, the use of neoantigen-based combination therapies, the inclusion of real-world data, and improved predictive modeling.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11944

What New Market Trends Are Reshaping theNeoantigen Targeted Therapies Market and Its Opportunities?

Principal businesses in the neoantigen targeted therapies sector are using strategic alliances as a tool to personalize cancer treatments, thereby addressing the issues of current immunotherapy in handling solid tumors. Strategic alliances are a mechanism by which companies utilize each other’s unique abilities and assets to attain mutual advantages and prosperity. For example, BioNTech SE, a biotech firm based in Germany, formed a strategic alliance with the UK Government in January 2023 to enhance personalized mRNA cancer immunotherapies. The goal of this partnership is to provide customized therapies to approximately 10,000 patients by 2030, touching on key sectors like the development of cancer immunotherapies, research into vaccines for infectious diseases, and establishing a research and development center in Cambridge. The operation will tap into the UK’s infrastructure for clinical trials and health data resources to improve patient enlistment and select trial locations for BioNTech’s mRNA treatments. BioNTech plans to kick off its inaugural clinical trials in the UK later this year, with a focus on cancer vaccines that may potentially get incorporated into standard treatment procedures if found successful.

Who Are the Leading Market Players Fueling Growth in the Neoantigen Targeted Therapies Market Trend?

Major companies operating in the neoantigen targeted therapies market include F. Hoffmann-La Roche AG, Merck and Co. Inc., Bristol Myers Squibb Company, Eli Lilly and Company, Kite Pharma Inc., Gilead Sciences Inc., Amgen Inc., Moderna Inc., BioNTech SE, Bavarian Nordic Inc., Advaxis Inc., Immatics NV, Precision Biologics Inc., Iovance Biotherapeutics Inc., Agenus Inc., Achilles Therapeutics Plc, Medigene AG, Gritstone Bio Inc., SQZ Biotechnologies Company, Aduro BioTech Inc., Inovio Pharmaceuticals Inc., Gradalis Inc., EpiVax Inc., ISA Pharmaceuticals BV, Vaxon Biotech SA, Ziopharm Oncology, Genocea Biosciences Inc., Cellular Biomedicine Group Inc., Immunovaccine Inc.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/neoantigen-targeted-therapies-global-market-report

How is the Global Neoantigen Targeted Therapies Market Segemented?

The neoantigen targeted therapies market covered in this report is segmented –

1) By Type: Monotherapy, Combination Therapy

2) By Immunotherapy Type: DNA Or RNA-Based Vaccines, Protein-Based Vaccines, Dendritic Cell Vaccines, TIL-Based Therapies

3) By Target Disease Indication: Colorectal Cancer, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Bone Cancer, Gynecological Cancer

4) By Route Of Administration: Intradermal, Intravenous, Subcutaneous

5) By Application: Medical Research Institution, Hospital, And Clinic, Other Applications

Subsegments:

1) By Monotherapy: Individual Neoantigen-Targeted Treatments

2) By Combination Therapy: Neoantigen-Targeted Therapies Combined With Other Immunotherapies, Neoantigen-Targeted Therapies Combined With Chemotherapy, Neoantigen-Targeted Therapies Combined With Targeted Therapies

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=11944&type=smp

Which Geographics are Influencing the Growth of the Neoantigen Targeted Therapies Market?

North America was the largest region in the neoantigen targeted therapies market in 2024. The regions covered in the neoantigen targeted therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Gobal Neoantigen Targeted Therapies Maret 2025, By The Business Research Company:

Acute Myeloid Leukemia Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/acute-myeloid-leukemia-global-market-report

Cancer biologics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

Point-of-Care Diagnostics Devices And Equipment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/point-of-care-diagnostics-devices-and-equipment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the neoantigen targeted therapies market grown in recent years?

The market size for neoantigen targeted therapies has experienced significant expansion recently. The growth is predicted to rise from $3.4 billion in 2024 to $4.72 billion in 2025, recording a compound annual growth rate (CAGR) of 38.7%. Factors contributing to this progress during the historic period include breakthroughs in genomic sequencing, progression of immunotherapy, insights into tumor immunology, successful clinical trials of checkpoint inhibitors, and advancements in molecular profiling.

How is the neoantigen targeted therapies market size expected to evolve during the forecast period?

The market size for neoantigen targeted therapies is predicted to experience significant expansion in the coming years, ballooning to a size of $16.01 billion in 2029, with a compound annual growth rate (CAGR) of 35.7%. This upward trend during the forecast period can be credited to progress in various areas, including bioinformatics, the broadening of precision medicine, the development of neoantigen vaccines, strategies combining therapies, and biomarker validation. The forecast period is also expected to see notable trends such as the management of neoantigen resistance, neoantigen-primed cell therapies, combinatorial therapies based on neoantigen, real-world data integration, and improved predictive models.

Get your neoantigen targeted therapies market report here!

https://www.thebusinessresearchcompany.com/report/neoantigen-targeted-therapies-global-market-report

Which key drivers are propelling the neoantigen targeted therapies market’s growth?

The growth of the neoantigen targeted therapies market is anticipated to be fueled by the escalating occurrence of cancer cases. The occurrence of cancer is defined as the sum of new cancer cases in a particular population over a certain period. Various types of cancer are often treated with neoantigen-targeted therapies in combination. As an example, the American Cancer Society (ACS), a voluntary health organization based in the United States, reported that in 2022, there were 1.9 million new cancer instances in the country, marking a substantial rise in comparison to previous years. Moreover, in 2022, around 609,360 deaths in the US were credited to cancer, highlighting the deep severity and effect of this illness on individuals and their families. Consequently, the escalating occurrence of cancer cases is contributing to the expansion of the neoantigen targeted therapies market.

What are the market segments in the neoantigen targeted therapies industry?

The neoantigen targeted therapies market covered in this report is segmented –

1) By Type: Monotherapy, Combination Therapy

2) By Immunotherapy Type: DNA Or RNA-Based Vaccines, Protein-Based Vaccines, Dendritic Cell Vaccines, TIL-Based Therapies

3) By Target Disease Indication: Colorectal Cancer, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Bone Cancer, Gynecological Cancer

4) By Route Of Administration: Intradermal, Intravenous, Subcutaneous

5) By Application: Medical Research Institution, Hospital, And Clinic, Other Applications

Subsegments:

1) By Monotherapy: Individual Neoantigen-Targeted Treatments

2) By Combination Therapy: Neoantigen-Targeted Therapies Combined With Other Immunotherapies, Neoantigen-Targeted Therapies Combined With Chemotherapy, Neoantigen-Targeted Therapies Combined With Targeted Therapies

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11944&type=smp

Which leading companies are shaping the growth of the neoantigen targeted therapies market?

Major companies operating in the neoantigen targeted therapies market include F. Hoffmann-La Roche AG, Merck and Co. Inc., Bristol Myers Squibb Company, Eli Lilly and Company, Kite Pharma Inc., Gilead Sciences Inc., Amgen Inc., Moderna Inc., BioNTech SE, Bavarian Nordic Inc., Advaxis Inc., Immatics NV, Precision Biologics Inc., Iovance Biotherapeutics Inc., Agenus Inc., Achilles Therapeutics Plc, Medigene AG, Gritstone Bio Inc., SQZ Biotechnologies Company, Aduro BioTech Inc., Inovio Pharmaceuticals Inc., Gradalis Inc., EpiVax Inc., ISA Pharmaceuticals BV, Vaxon Biotech SA, Ziopharm Oncology, Genocea Biosciences Inc., Cellular Biomedicine Group Inc., Immunovaccine Inc.

What key trends are currently impacting the neoantigen targeted therapies market’s development?

Major firms in the neoantigen targeted therapies market are strategizing partnerships to customize cancer treatments and address the limitations of existing immunotherapy in managing solid tumors. Such strategic partnerships involve businesses utilizing each other’s capabilities and assets for reciprocal benefits and achievement. For example, in January 2023, the Germany-based biotech firm, BioNTech SE, entered into a partnership with the UK Government. This partnership’s goal is to offer personalized mRNA cancer immunotherapies to up to 10,000 patients by the year 2030. The collaboration encompasses numerous key sectors, such as cancer immunotherapy development, infectious disease vaccine research, and the establishment of a research and development centre in Cambridge. This joint effort will make use of the UK’s clinical trial infrastructure and health data resources to enhance patient enrolment and choose locations for BioNTech’s mRNA treatments’ trials. The company anticipates launching its inaugural clinical trials in the UK later this year, concentrating on cancer vaccines that may potentially be incorporated into routine treatment procedures if deemed effective.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11944

Which geographic areas are influencing the growth of the neoantigen targeted therapies market?

North America was the largest region in the neoantigen targeted therapies market in 2024. The regions covered in the neoantigen targeted therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Acute Myeloid Leukemia Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/acute-myeloid-leukemia-global-market-report

Cancer biologics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

Point-of-Care Diagnostics Devices And Equipment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/point-of-care-diagnostics-devices-and-equipment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: